{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Core Week 26"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"title":"Core Week 35"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"To test proximal muscle strength patients should be placed in a low seated position (for instance on an examination room stool). They should be asked to extend the arms in front of them. From this seated position patients will be asked to stand up. Patients will be evaluated using the following scale: 3. - completely unable to stand 2. - able to stand only by using arms as assistance\n\n1\\. - able to stand after several efforts without using arms as assistance 0. - able to stand easily with arms extended","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Baseline up to week 267","title":"Number of Patients With Shift From Standing Easily to Not Being Able to Stand","type":"SECONDARY","unitOfMeasure":"participants"}